A Phase 2 Multicenter Open-Label Extension Study to Evaluate the Safety and Tolerability of AK002 in Patients with Eosinophilic Gastritis and/or Eosinophilic Gastroenteritis
Enrolling By Invitation
99 years or below
All
Phase
2
6 participants needed
1 Location
Brief description of study
AK002 is a humanized non-fucosylated immunoglobulin G1 (IgG1) monoclonal antibody to the inhibitory receptor Siglec-8, present on mast cells, eosinophils, and basophils. Binding of AK002 to Siglec-8 induces a signal that inhibits mast cell activation and can lead to apoptosis in eosinophils. In the presence of effector cells (such as natural killer [NK] cells), AK002 binding to Siglec-8 depletes circulating eosinophils by ADCC and may reduce eosinophil and mast cell numbers in tissue. This profile of activity may provide clinical benefit in diseases in which these cell types play a role, such as EG and/or EGE.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: Gastroenteritis
-
Age: 99 years or below
-
Gender: All
Updated on
04 Aug 2024.
Study ID: 832315
If you need assistance finding a non-cancer clinical research study or if you have any questions, please email psom-ocr@pobox.upenn.edu
For Cancer trials contact Penn Medicine's Cancer Trial Navigator at: PMCancerResearch@pennmedicine.upenn.edu or 215-349-8245
